Multidisciplinary and integrated solutions to influence and guide a drug discovery program from inception to IND filing
With comprehensive and expansive capabilities in biology, GVK BIO offers high-quality, cost-effective solutions across the pharma and biotech value chain. Biological assessment of New Molecular Entities (NMEs) plays a crucial role in ascertaining structure activity relationships, potency, selectivity, druggability, in vitro and in vivo efficacy evaluations.
- 100+ scientists in protein production, cell-line engineering, assay development and screening, in vitro toxicology, in vitro ADME, pharmacokinetics, in vivo efficacy and safety pharmacology.
- Access to multiple partnering options across the drug discovery chain, ensuring seamless, efficient and rapid implementation of research projects
- 100+ clients in the pharmaceutical, agrochemical and cosmeceutical sectors
- Our infrastructure includes an AAALAC approved vivarium and world class laboratories, instrumentation, and automation
- Highly experienced and globally trained scientific leadership
Custom solutions for drug discovery
From hit identification to clinical candidate selection: